Sanofi, Regeneron drug successors may trail rivals, Citi says
Potential successors to Sanofi and Regeneron Pharmaceuticals' Dupixent drug may not perform as well as rival treatments being developed by Pfizer and AbbVie, according to Citi analysts.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.